Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
de la Piedra C, Alcaraz A, Bellmunt J, Meseguer C, Gómez-Caamano A, Ribal MJ, Vázquez F, Anido U, Samper P, Esteban E, Álvarez-Ossorio JL, Lara PC, San José LA, Contreras JA, del Alba AG, González-Gragera B, Tabernero AJ, González-Enguita C, Fernández JM, García-Escudero A, Gómez-Veiga F, Méndez MJ, Segarra J, Virizuela JA, Carles J, Lassa A, Calderero V, Constela M, Delgado D, Mañas A, Murias A, Reynes G, Rodriguez B, Rubio G, Sánchez E, Unda M, Solsona E, Martínez-Javaloyas JM, Comet-Batlle J, Quicios C, Martín-Fernández M, Mahillo-Fernández I, Morote J. de la Piedra C, et al. Among authors: carles j. Br J Cancer. 2013 Jun 25;108(12):2565-72. doi: 10.1038/bjc.2013.270. Epub 2013 May 30. Br J Cancer. 2013. PMID: 23722472 Free PMC article. Clinical Trial.
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Carles J, Esteban E, Climent M, Font A, Gonzalez-Larriba JL, Berrocal A, Garcia-Ribas I, Marfa X, Fabregat X, Albanell J, Bellmunt J; Spanish Oncology Genito Urinary Group Study Group. Carles J, et al. Ann Oncol. 2007 Aug;18(8):1359-62. doi: 10.1093/annonc/mdm160. Ann Oncol. 2007. PMID: 17693649 Free article. Clinical Trial.
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Carles J, Font A, Mellado B, Domenech M, Gallardo E, González-Larriba JL, Catalan G, Alfaro J, Gonzalez Del Alba A, Nogué M, Lianes P, Tello JM. Carles J, et al. Br J Cancer. 2007 Nov 5;97(9):1206-10. doi: 10.1038/sj.bjc.6604030. Epub 2007 Oct 23. Br J Cancer. 2007. PMID: 17955053 Free PMC article. Clinical Trial.
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.
Bellmunt J, González-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Bellmunt J, et al. Among authors: carles j. Ann Oncol. 2011 Dec;22(12):2646-2653. doi: 10.1093/annonc/mdr023. Epub 2011 Mar 21. Ann Oncol. 2011. PMID: 21427062 Free article. Clinical Trial.
[Castration-resistant prostate cancer: where are we going?].
Alcaraz A, Medina R, Maroto P, Climent MÁ, Castellano D, Carles J. Alcaraz A, et al. Among authors: carles j. Actas Urol Esp. 2012 Jun;36(6):367-74. doi: 10.1016/j.acuro.2011.10.010. Epub 2011 Dec 19. Actas Urol Esp. 2012. PMID: 22188754 Review. Spanish.
[Recomendations on the management of controversies in advanced castrate-resistant prostate cancer].
Cózar JM, Solsona E, Morote J, Miñana B, Maroto JP, González Del Alba A, Climent MA, Carles J, Alcaraz A, Castellano D; Asociación Española de Urología; Grupo de Urología Oncológica; Grupo Español de Oncología Genitourinaria. Cózar JM, et al. Among authors: carles j. Actas Urol Esp. 2012 Nov-Dec;36(10):569-77. doi: 10.1016/j.acuro.2012.06.004. Epub 2012 Sep 19. Actas Urol Esp. 2012. PMID: 22999347 Spanish.
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Alcaraz A, González-López R, Morote J, de la Piedra C, Meseguer C, Esteban E, Climent M, González-Gragera B, Alvarez-Ossorio JL, Chirivella I, Mellado B, Lara PC, Vázquez F, Contreras JA, Carles J, Murias A, Calderero V, Comet-Batlle J, González-Del Alba A, León-Mateos L, Mañas A, Segarra J, Lassa A, González-Enguita C, Méndez MJ, Samper P, Unda M, Mahillo-Fernández I, Bellmunt J; TUGAMO GROUP. Alcaraz A, et al. Among authors: carles j. Br J Cancer. 2013 Jul 9;109(1):121-30. doi: 10.1038/bjc.2013.272. Epub 2013 Jun 25. Br J Cancer. 2013. PMID: 23799855 Free PMC article.
LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer risk.
Tajuddin SM, Amaral AF, Fernández AF, Chanock S, Silverman DT, Tardón A, Carrato A, García-Closas M, Jackson BP, Toraño EG, Márquez M, Urdinguio RG, García-Closas R, Rothman N, Kogevinas M, Real FX, Fraga MF, Malats N; Spanish Bladder Cancer/EPICURO Study investigators. Tajuddin SM, et al. Br J Cancer. 2014 Apr 15;110(8):2123-30. doi: 10.1038/bjc.2014.67. Epub 2014 Mar 4. Br J Cancer. 2014. PMID: 24595004 Free PMC article.
299 results